It has been a highly productive summer period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.
Anders Tuv BioLeader Interview - Anders Tuv, Chief Investment Officer at Radforsk, Norway (May 2022) Anders is Chief Investment Officer of the life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional in the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders also holds several chairman and non-executive director positions. Key milestones in your career journey to date? My time as managing consultant at Ernst & Young Advisory, focused on the healthcare industry, [...]
Agnete Fredriksen BioLeader Interview - Agnete Fredriksen, Co-Founder, Chief Innovation & Strategy Officer at Nykode Therapeutics AS (April 2022) Agnete is a co-founder of Nykode Therapeutics and served as Chief Scientific Officer from 2007-2021, leading the organisation’s scientific strategy. Her previous employers include Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. Agnete holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first [...]
Camilla Simpson BioLeader Interview - Camilla Simpson, Chief Executive Officer, Zehna Therapeutics (April 2022) Camilla Simpson has over two decades of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career. Currently, Camilla is CEO of Zehna Therapeutics, Inc a seed stage startup and spin out of the Cleveland Clinic. Prior to this, Camilla founded Rare Strategic LLC where she provided strategic advice to early-stage [...]
Susan Hill BioLeader Interview - Susan Hill, Chief Executive Officer of Mestag Therapeutics and Venture Partner with SV Health Investors (February 2022) Susan Hill is founding Chief Executive Officer of Mestag Therapeutics, a Cambridge (UK)- based biotech company developing new therapeutics for inflammatory disease and cancer. Mestag explores the role of fibroblasts in influencing the immune environment in disease, supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company raised seed financing of $45m in 2021 and was recognized on the 2021 Fierce 15 list of [...]
It has been a highly productive recent period for PIR International, with growth across all facets of Life Sciences. We are pleased to share a selection of our recent appointments with our valued clients across the UK, Europe and the US.
The Board of PIR International, a leading provider of executive search and interim services to the global life science industry, today announced the finalisation of an MBO with the executive team of the business, Sally Hope, Stuart Penney, and Tom Bradley, who will acquire the majority of shares from the founder, Carolyn Douthwaite. Carolyn founded the business in 2006, initially focused on the provision of senior interims to major life science companies. Since then, the range of services has evolved, in line with client demand, and particularly the growth of the services to early stage, investor backed biotechs. This has [...]
Billy Boyle BioLeader Interview - Billy Boyle, Chief Executive Officer, Owlstone Medical (January 2022) Billy Boyle is an engineering graduate from the University of Cambridge. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004 with the goal of developing the applications of field asymmetric ion mobility spectroscopy (FAIMS). Billy started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum [...]
Neelam Patel BioLeader Interview - Neelam Patel, Chief Executive Officer MedCity (January 2022) Neelam is CEO of MedCity, the life sciences cluster organisation for London, which plays a pivotal role in bridging industry, NHS and academia to boost innovation and economic growth. Neelam’s extensive experience spans the private, public and not-for-profit sectors. She has worked with the Association of British Pharmaceutical Industries, the European Innovative Medicines Initiative and collaborated with NHS England, NICE and Public Health England. Neelam regularly supports companies with R&D, advising on the UK regulatory and access landscape, and is actively working to shape delivery of [...]
As formerly rock-solid revenue streams dry up, many life sciences companies are paying closer than ever scrutiny to operating costs. With people costs one of the greatest, pressure is on the human resources team to prove its value. In this article, Tom Bradley discusses how the hiring process can be sharpened up, leading to improved accountability and clarity of HR’s value to the business.Rationalisation, leverage of scale, consolidation, efficiencies: this is the ‘new normal’ for the global pharmaceutical industry. Whether it’s grappling with so-called patent cliffs, price cuts and reimbursement restrictions, increasing regulation, competition from generic manufacturers – perhaps even [...]